Thu, Jun 13, 2024
Torrent Pharmaceuticals said on Wednesday that its that it Indrad, Gujarat-based manufacturing facility had received Form 483 from the US FDA. The pharma firm said that the US FDA had conducted a pre-approval inspection (PAI) and a GMP inspection at the its manufacturing facility in Indrad, Gujarat, from June 3 to June 12.
More >
Mon, May 27, 2024
Results Review : Divi's Laboratories, Torrent Pharma, Aurobindo Pharma, Glenmark Pharma, United Spirits, Hindalco, Ashok Leyland और NTPC के नतीजे कैसे रहे? नतीजों के बाद किन शेयरों में करें खरीदारी? जानिए एनालिसिस Anil Singhvi से.
Torrent Pharma Q4 results: Torrent Pharmaceuticals shares jumped nearly seven per cent on Monday, May 27 after the pharma company reported a strong set of March quarter results.
Wed, May 25, 2022
Q4 Results 2022: Torrent Pharma announced its March quarter results on Wednesday. The company posted Rs 118 crore Q4 loss on impairment provision. Meanwhile, Bata India and Kolte-Patil also declared their January-March quarter result
Thu, Feb 03, 2022
Shares of Torrent Pharmaceutical, Wendt (India) and Cosmo Films would be in action on Thursday as the board of management of these companies have fixed record dates for interim dividend as February 3, 2022
Thu, Jan 27, 2022
Shares of Torrent Pharma were locked in lower circuit as they declined 13 per cent to Rs 2704.80 per share in Thursday's intraday trade on the BSE.
Tue, Apr 13, 2021
In conversation with Zee Business Managing Editor Anil Singhvi, market analyst Siddharth Sedani on Tuesday recommended stocks centred on the 'healing health' theme.
Tue, Feb 09, 2021
Torrent Pharmaceuticals reported healthy performance for Q3 FY21, led by a slightly better than expected operating performance. Revenues for the quarter stood at Rs 1995 cr, up by a meager 1.5% yoy and were in line with the estimates. The operating margins for the quarter stood at 30.4%, up by 296 bps yoy, driven by savings in the other expenses.
Thu, Jan 14, 2021
HDFC Securities see several growth catalysts across key markets and product categories (inhalers, biosimilars, complex injectables) playing out over the next 2-3 years for Indian pharma companies. The investments made over the last few years leave them well placed to capitalise on these opportunities. With cost bases pruned and operating leverage benefits, the sector is poised to grow at 21% earnings CAGR and witness ROCE improvement of 430bps to 15% over FY20- 23e.
Tue, Dec 15, 2020
Among the top 30 companies Mylan clocked the highest growth of 144% for November followed by Glenmark Pharma(+11%), IPCA Labs (+10%) and Ajanta Pharma(+10%) clocking double digit growth while Novartis, Micro, Indoco Remedies, FDC & Mankind Pharma were impacted the most. With 144% growth for the month (sales of Rs 920 m), Mylan has been the standout performer for the month primarily aided by Rs 540 mn sales contribution from its COVID treatment drug, Desrem. Notably, Desrem was the second largest selling brand in IPM for Nov20. Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life were among some local listed players that clocked a single digit growth.
Fri, Oct 09, 2020
CLSA believes that fundamentals for the pharma sector in 2020 are much healthier than even in 2015.
Fri, Jul 31, 2020
Drug firm Torrent Pharmaceuticals reported a 48.61 per cent rise in its consolidated net profit to Rs 321 crore for the quarter ended June 30, 2020, mainly on account of robust sales in the Indian market.
Sun, Jun 10, 2018
CPI, WPI and IIP will be presented in upcoming week and domestic indices will move as per the performances of these indicators.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
